Letter to the Editor Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience DOI: 10 .4103/sajc.sajc_169_19
Dear Editor, Lung cancer treatment is a rapidly evolving and an excellent example of precision medicine. The outcome of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has improved significantly with recent report showing the survival of 56% at 4 years. [1] This has been possible due to the availability of effective sequential treatment. One of the important drugs has been lorlatinib. This has found to be effective in second-line setting after crizotinib. [2] There has been no data from India. We retrospectively analyzed the data of patients receiving lorlatinib in our hospital. Patients diagnosed with ALK-positive advanced NSCLC who have received lorlatinib between January 2018 and February 2019 patients who have progressed on crizotinib were included in the study. Lorlatinib (Pfizer Oncology, Groton, CT, USA) was administered orally in a tablet form at a starting dose of 100 mg once daily continuously in 21-day cycles.
The details of these patients were obtained from the prospective lung cancer audit database that is maintained in the department of medical oncology. Demography (age, gender, comorbidity, and smoking status), disease status, and therapy details were recorded. ALK amplified status was ascertained either by later confirmed as cancer on pathology and are managed by individual specialty. We do not claim to register all such cases as some of them may not be referred for cancer registry data entry. Moreover, sites where facility for biopsy are still suboptimal due paucity of infrastructure, manpower, and skills, especially for eloquent location such as lung mass, retroperitoneal sarcoma, and brain tumors may be under represented.
Conclusion
Gallbladder and head-and-neck cancer are the most common cancer seen in Bihar with both showing upward trend, whereas breast and cervical cancers are gradually decreasing. Government authorities need to invest more to provide sufficient manpower, infrastructure, and financial resources to tackle this rising cancer burden in Bihar. This also merits more stringent measures for ensuring tobacco ban and exploring methods to reduce chronic exposure of heavy metals.
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There are no conflicts of interest. Tables 1 and 2 tabulate baseline characteristics and side effects of lorlatinib. The estimated median PFS in our study was 9.0 months (range: 5.6 months-12.3 months) [ Figure 1 ]. Out of 9 evaluable patients, 2 (20%) and 5 (50%) has complete and partial responses, respectively [ Table 1 ].
Our results are comparable to that reported in the literature. [2] However, median duration of response in our cohort was lesser (9 months) in comparison to that reported in literature (12.5 months) . Reason for such discrepant data (Continue on page 225...)
